Inflammatory myofibroblastic tumors of the bladder in a 20-year-old female

Inflammatory myofibroblastic tumors of the bladder in a 20-year-old female

Bibliographic Details
Main Authors:	Yijie Liu, Jiansong Wang
Format:	Article
Language:	English
Published:	Elsevier 2023-12-01
Series:	Asian Journal of Surgery
Subjects:	Renal pelvis Mucus Adenocarcinoma Pathology ALK Crizotinib
Online Access:	http://www.sciencedirect.com/science/article/pii/S1015958423011867

Similar Items

Long‐term response to crizotinib in a 17‐year‐old boy with treatment‐naïve ALK‐positive non‐small‐cell lung cancer
by: Giacomina Megaro, et al.
Published: (2022-03-01)

A case of ALK-rearranged lung adenocarcinoma associated with syndrome of inappropriate antidiuretic hormone
by: Yoshihiro Miyashita, et al.
Published: (2020-01-01)

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
by: Jiacong Wei, et al.
Published: (2018-01-01)

Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
by: Zhang X, et al.
Published: (2023-01-01)

Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report
by: Xueqian Wu, et al.
Published: (2020-06-01)

Secondary mutant ALK-I1171s in pituitary metastases from a patient with ALK fusion-positive advanced lung adenocarcinoma: A case report and literature review
by: Dan Han, et al.
Published: (2022-10-01)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
by: Zihua Zou, et al.
Published: (2022-01-01)

Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer
by: Li MA, et al.
Published: (2014-12-01)

Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report
by: Zhan Wang, et al.
Published: (2022-02-01)

Clinical Efficacy of Crizotinib in Advanced ALK Positive  Non-small Cell Lung Cancer
by: Jing ZHAO, et al.
Published: (2015-10-01)

A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib
by: Min Zhang, MBBS, et al.
Published: (2021-02-01)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
by: Rothschild SI
Published: (2016-05-01)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
by: Mezquita L, et al.
Published: (2018-01-01)

Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report
by: Huamiao Zhou, et al.
Published: (2021-06-01)

Incidence and patterns of <it>ALK</it> FISH abnormalities seen in a large unselected series of lung carcinomas
by: Dai Zunyan, et al.
Published: (2012-12-01)

A Novel Intergenic Region (chr2: 30,316,870)-ALK Fusion in a Patient with Lung Adenocarcinoma Responding to Crizotinib Combined with Pemetrexed Treatment: A Case Report
by: Zhou D, et al.
Published: (2024-03-01)

Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib
by: Yuhang Zhou, et al.
Published: (2023-11-01)

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
by: Sara Verdura, et al.
Published: (2022-12-01)

Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review
by: Satvik Khaddar, et al.
Published: (2022-07-01)

ALK inhibitors, a pharmaceutical perspective
by: Arturo eGalvani, et al.
Published: (2012-02-01)

Efficacy and Safety of Crizotinib in Advanced or Recurrent  ALK-positive Non-small Cell Lung Cancer
by: Xiaoyan LI, et al.
Published: (2019-08-01)

Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring ALK-IGFBP5 fusion
by: Ting Zhao, et al.
Published: (2023-03-01)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition
by: Edyta M. Urbanska, et al.
Published: (2020-04-01)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
by: Yen-Ting Lin, et al.
Published: (2019-09-01)

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
by: Emilio Francesco Giunta, et al.
Published: (2022-06-01)

Mucinous adenocarcinoma of the renal pelvis with adenocarcinoma in situ of the ureter
by: Vandana Raphael, et al.
Published: (2011-01-01)

Good Tolerance to Full-Dose Crizotinib in a Patient with Anaplastic Lymphoma Receptor Tyrosine Kinase-Rearranged Lung Adenocarcinoma and Preexisting Renal Impairment
by: Adeline Rosoux, et al.
Published: (2017-05-01)

ALK Gene Translocation in Inflammatory Myofibroblastic Tumor of the Urinary Bladder: A Case Report
by: Kimiaki Takagi, et al.
Published: (2015-09-01)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2023-08-01)

Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics
by: Ilija Nenadić, et al.
Published: (2017-07-01)

Association of anticoagulant use with clinical outcomes from crizotinib in ALK‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001
by: Terry L. Ng, et al.
Published: (2022-12-01)

Focus on Alectinib and Competitor Compounds for Second Line Therapy in ALK Rearranged NSCLC
by: Samuel J Klempner, et al.
Published: (2016-11-01)

Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
by: Kunyan Sun, et al.
Published: (2021-06-01)

How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas ALK+ Therapy: A Case Report
by: Antonello Sica, et al.
Published: (2021-01-01)

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
by: Chang Liu, et al.
Published: (2019-10-01)

Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib
by: Xiaoqian Zhai, et al.
Published: (2023-03-01)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01)

ALK Inhibitors-Induced M Phase Delay Contributes to the Suppression of Cell Proliferation
by: Sirajam Munira, et al.
Published: (2020-04-01)

Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
by: Akhil Kapoor, et al.
Published: (2023-04-01)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
by: Ryohei Katayama, et al.
Published: (2016-01-01)